Want to see CVSI full AI Analyst Report?
Top Page
CV Sciences
(OTC:CVSI)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.01
▼(-45.00% Downside)
Action:Reiterated
Date:09/17/26
The score is primarily held down by weak financial performance (declining revenue, ongoing losses, and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Valuation does not provide meaningful support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Resilient Gross Margin
Gross margin has remained near 49% despite the recent revenue contraction, showing that product-level economics have been relatively stable. If maintained, this margin provides a foundation for operating improvement should sales recover, although current costs still prevent the company from reaching profitability.
Negative Factors
Declining Revenue
The sustained decline in revenue signals weakening demand or distribution performance rather than a single isolated quarterly setback. Lower sales reduce the scale available to absorb operating expenses, making it harder for stable gross margins and new products to translate into sustainable operating profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Resilient Gross Margin
Gross margin has remained near 49% despite the recent revenue contraction, showing that product-level economics have been relatively stable. If maintained, this margin provides a foundation for operating improvement should sales recover, although current costs still prevent the company from reaching profitability.
Read all positive factors
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.85M
Dividend YieldN/A
Average Volume (3M)720.41K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-14.90%
EPS Growth-22.35%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding225,829,130
10 Day Avg. Volume402,715
30 Day Avg. Volume720,409
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap2.10
Enterprise Value/Revenue0.47
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda-5.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division...
How the Company Makes Money
CV Sciences makes money primarily by selling hemp-derived CBD consumer products. Its core revenue stream is product sales (e.g., ingestible CBD formulations like gummies, capsules, tinctures, and related wellness items, as well as topical products...
CV Sciences Earnings Call Summary
Earnings Call Date:Aug 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.Positive Updates
Revenue Resilience
Generated revenue of $3.0 million in Q2 2026; while down 7% sequentially (from $3.2M) and 17% year-over-year, management emphasized resilience in a constrained operating environment.
Negative Updates
Top-Line Decline and Volume Pressure
Revenue decreased 7% sequentially and 17% year-over-year to $3.0 million, driven primarily by a 15% decline in unit sales—reflecting continued category contraction and competitive pressure.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Resilience
Generated revenue of $3.0 million in Q2 2026; while down 7% sequentially (from $3.2M) and 17% year-over-year, management emphasized resilience in a constrained operating environment.
Read all positive updates
Company Guidance
Management guided that the company will prioritize scaling and profitable growth by expanding non‑cannabinoid +PlusHLTH product launches and select international expansion via Cultured Foods while continuing strict cost and working‑capital discipline to drive margins and cash flow. Key metrics referenced: Q2 revenue of $3.0M (down 7% sequential, 17% YoY; unit sales down 15%), gross margin 48.6% (48.9% in Q1; 50.9% year‑ago), SG&A $1.7M (down ~7.9% sequential/~10% YoY), adjusted EBITDA loss $0.1M (flat vs Q1), operating loss $0.3M, net loss $0.8M, positive operating cash flow of ~ $20k in Q2 (also positive in Q1), cash ≈ $0.3M, inventory ≈ $4.0M (vs $4.1M year‑end), and convertible note fair value $1.0M after ~ $0.7M of conversions — with an aim to reach sustainable positive operating cash flow and to remain flexible pending regulatory timing changes (potential delay of Nov 12, 2026 provisions to Dec 11, 2026).CV Sciences Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.74M | 13.79M | 15.71M | 16.00M | 16.20M | 20.05M |
| Gross Profit | 6.26M | 6.75M | 7.17M | 7.08M | 5.55M | 8.62M |
| EBITDA | -1.09M | -562.00K | -1.86M | 3.85M | -5.66M | -14.00M |
| Net Income | -2.01M | -958.00K | -2.39M | 3.10M | -8.21M | -15.55M |
Balance Sheet | ||||||
| Total Assets | 6.52M | 6.96M | 7.93M | 26.35M | 12.74M | 18.07M |
| Cash, Cash Equivalents and Short-Term Investments | 266.00K | 278.00K | 454.00K | 1.32M | 611.00K | 1.38M |
| Total Debt | 1.25M | 1.61M | 779.00K | 442.00K | 1.53M | 922.00K |
| Total Liabilities | 4.95M | 5.49M | 6.13M | 23.44M | 13.51M | 14.52M |
| Stockholders Equity | 1.57M | 1.47M | 1.79M | 2.90M | -777.00K | 3.54M |
Cash Flow | ||||||
| Free Cash Flow | -522.00K | -516.00K | -879.00K | 2.25M | -1.89M | -7.52M |
| Operating Cash Flow | -492.00K | -407.00K | -861.00K | 2.25M | -1.89M | -7.49M |
| Investing Cash Flow | -30.00K | -109.00K | -28.00K | -156.00K | 0.00 | -35.00K |
| Financing Cash Flow | -98.00K | 337.00K | 32.00K | -1.39M | 1.12M | 4.37M |
CV Sciences Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Positive
35.39
Neutral
-55.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.39 is Neutral, neither overbought nor oversold. The STOCH value of -55.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $38.24M | -0.58 | -118.89% | ― | 33.82% | 34.05% | |
49 Neutral | $40.27M | -2.87 | -27.42% | ― | -100.00% | 95.90% | |
45 Neutral | $5.11M | -1.49 | -34.25% | ― | 10.01% | 95.01% | |
44 Neutral | $3.36M | -1,062.50 | -3.03% | ― | -11.91% | -285.26% | |
41 Neutral | $2.85M | -1.21 | -132.06% | ― | -14.90% | -22.35% |
* Healthcare Sector Average
CVSI
CV Sciences
0.01
-0.03
-72.73%
YCBD
cbdMD
0.46
-0.84
-64.92%
COSM
Cosmos Holdings
0.38
-0.64
-62.75%
IMCC
IM Cannabis Corp
2.04
-60.06
-96.71%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.21
-10.13
-75.93%
CV Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
CV Sciences Reports Q2 Results Amid Regulatory Reprieve
Negative
Aug 13, 2026
On August 13, 2026, CV Sciences reported second-quarter 2026 results showing revenue of $3.0 million, down 17.5% from a year earlier, as restrictive federal and state regulations weighed on sales volumes and reduced units sold by 14.9%. Despite th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.